Clean Yield Group lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 30.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,521 shares of the biopharmaceutical company’s stock after buying an additional 12,581 shares during the period. Gilead Sciences makes up approximately 1.4% of Clean Yield Group’s portfolio, making the stock its 25th largest position. Clean Yield Group’s holdings in Gilead Sciences were worth $3,544,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mutual of Omaha Bank Wealth Management increased its holdings in Gilead Sciences by 8.6% in the 1st quarter. Mutual of Omaha Bank Wealth Management now owns 10,458 shares of the biopharmaceutical company’s stock valued at $680,000 after purchasing an additional 830 shares during the last quarter. Bailard Inc. increased its holdings in Gilead Sciences by 13.6% in the 1st quarter. Bailard Inc. now owns 49,565 shares of the biopharmaceutical company’s stock valued at $3,222,000 after purchasing an additional 5,929 shares during the last quarter. Mechanics Bank Trust Department increased its holdings in Gilead Sciences by 8.7% in the 1st quarter. Mechanics Bank Trust Department now owns 9,326 shares of the biopharmaceutical company’s stock valued at $606,000 after purchasing an additional 747 shares during the last quarter. Ellis Investment Partners LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at approximately $131,000. Finally, Cooper Haims Advisors LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at approximately $1,259,000. Institutional investors and hedge funds own 79.94% of the company’s stock.
In related news, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $64.14, for a total value of $173,178.00. Following the completion of the sale, the director now directly owns 57,560 shares of the company’s stock, valued at $3,691,898.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,602 shares of company stock valued at $1,863,445. 0.20% of the stock is owned by corporate insiders.
Several research firms recently weighed in on GILD. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 23rd. Mizuho reiterated a “buy” rating and issued a $88.00 target price on shares of Gilead Sciences in a report on Tuesday, February 26th. Citigroup downgraded shares of Gilead Sciences from a “buy” rating to a “neutral” rating and dropped their target price for the company from $100.00 to $75.00 in a report on Tuesday, February 12th. Raymond James set a $83.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, May 3rd. Finally, ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, May 1st. Nine research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $81.00.
Shares of Gilead Sciences stock traded down $0.02 during trading on Wednesday, hitting $66.50. 5,232,893 shares of the stock were exchanged, compared to its average volume of 7,266,858. The stock has a market cap of $84.60 billion, a P/E ratio of 10.81, a price-to-earnings-growth ratio of 0.81 and a beta of 1.14. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $79.61. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.48 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a $0.63 dividend. The ex-dividend date is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a yield of 3.79%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Trading Strategy
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.